What SALIX PHARMACEUTICALS LTD's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Scruggs Rick D | Executive Vice President | Apr 01 | Disposition to Issuer · D | −48,006 | $173.00 | −$8.31M | 0 |
| Scruggs Rick D | Executive Vice President | Apr 01 | Tender Offer · U | −26,956 | $173.00 | −$4.66M | 0 |
| Bertrand William C Jr | See Remarks | Apr 01 | Disposition to Issuer · D | −28,289 | $173.00 | −$4.89M | 0 |
| Bertrand William C Jr | See Remarks | Apr 01 | Tender Offer · U | −2,969 | $173.00 | −$514K | 0 |
| Forbes William P | President, Medical, R&D & CDO | Apr 01 | Disposition to Issuer · D | −51,714 | $173.00 | −$8.95M | 0 |
| Sirgo Mark A | Director | Apr 01 | Disposition to Issuer · D | −6,370 | $173.00 | −$1.1M | 0 |
| Sirgo Mark A | Director | Apr 01 | Tender Offer · U | −31,057 | $173.00 | −$5.37M | 0 |
| Chappell John F | Director | Apr 01 | Disposition to Issuer · D | −28,644 | $173.00 | −$4.96M | 0 |
| Chappell John F | Director | Apr 01 | Disposition to Issuer · D | −294,120 | $173.00 | −$50.9M | 0 |
| Keane William P | Director | Apr 01 | Disposition to Issuer · D | −6,370 | $173.00 | −$1.1M | 0 |
| Keane William P | Director | Apr 01 | Tender Offer · U | −32,790 | $173.00 | −$5.67M | 0 |
| Creech Timothy J | See Remarks | Apr 01 | Disposition to Issuer · D | −21,372 | $173.00 | −$3.7M | 0 |
| Creech Timothy J | See Remarks | Apr 01 | Tender Offer · U | −4,065 | $173.00 | −$703K | 0 |
| D Alonzo Thomas | Acting President and CEO | Apr 01 | Tender Offer · U | −6,500 | $173.00 | −$1.12M | 0 |
| D Alonzo Thomas | Acting President and CEO | Apr 01 | Tender Offer · U | −260 | $173.00 | −$45K | 0 |
| D Alonzo Thomas | Acting President and CEO | Apr 01 | Tender Offer · U | −1,080 | $173.00 | −$187K | 0 |
| D Alonzo Thomas | Acting President and CEO | Apr 01 | Tender Offer · U | −10,450 | $173.00 | −$1.81M | 0 |
| D Alonzo Thomas | Acting President and CEO | Apr 01 | Disposition to Issuer · D | −21,032 | $173.00 | −$3.64M | 0 |
| D Alonzo Thomas | Acting President and CEO | Apr 01 | Tender Offer · U | −74,555 | $173.00 | −$12.9M | 0 |
| Forbes William P | President, Medical R&D and CDO | Mar 09 | Open-market sale · S | −42,880 | $157.84 | −$6.77M | 51,714 |
Loading...
